Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07318259 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

Name: Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE — clinical trial record (NCT07318259)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorChongqing Precision Biotech Co., Ltd

Started2026-01-26

View on ClinicalTrials.gov ↗

Record status

This record was last updated February 3, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-02-02

Study Status v1

Start dateestimated 2026-01→confirmed 2026-01-26

2025-12-28

Original filing

Chongqing Precision Biotech Co., Ltd

36 trials monitored

See 1 trial at risk

Lupus (SLE)

648 trials monitored

See 25 trials at risk

This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous BCMA/CD70-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.

Trial Details

NCT Number	NCT07318259
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	Systemic Lupus Erythematosus
Enrollment	18 participants
Start Date	2026-01-26
Primary Completion	2026-07 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2026-02-03